research use only
Cat.No.S5058
| Related Targets | CFTR CRM1 CD markers AChR Calcium Channel Sodium Channel Potassium Channel GABA Receptor TRP Channel ATPase |
|---|---|
| Other Proton Pump Inhibitors | Bafilomycin A1 (Baf-A1) Ilaprazole Tenatoprazole Ilaprazole sodium PF-3716556 Ufiprazole |
|
In vitro |
DMSO
: 16 mg/mL
(40.11 mM)
Water : Insoluble |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 398.9 | Formula | C22H23FN4.HCl |
Storage (From the date of receipt) | |
|---|---|---|---|---|---|
| CAS No. | 178307-42-1 | -- | Storage of Stock Solutions |
|
|
| Synonyms | YH1885 | Smiles | CC1C2=CC=CC=C2CCN1C3=NC(=NC(=C3C)C)NC4=CC=C(C=C4)F.Cl | ||
| Targets/IC50/Ki |
Proton pump
H(+)/K(+)-ATPase
|
|---|---|
| In vitro |
Revaprazan Hydrochloride reversibly inhibits H+/K+-ATPase via binding to the K+-binding site of the pump. This reversibility leads to fewer adverse events. This compound could inhibit H.pylori-induced COX-2 expression by blocking phosphorylation of IκB-α and Akt signaling in AGS cells. It could impose significant anti-inflammatory actions on H.pylori infection beyond acid suppression.
|
| In vivo |
Pharmacokinetic studies of revaprazan hydrochloride in rats and dogs showed the drug had a low oral bioavailability, which was speculated to be due to first pass effect and poor water solubility of this compound.
|
References |
|
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.